Rapid Peanut OIT Dose Escalation Protocol
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral immunotherapy (OIT) protocols for peanut allergy are lengthy, costly, and associated with high adverse event rates, leading to low compliance and ineffective desensitization or sustained unresponsiveness, particularly during the dose escalation phase.
Innovation Solution
A rapid dose escalation protocol for peanut OIT that increases the peanut allergen dose from 5 mg to 200 mg or more within 4 to 9 weeks without prior anti-IgE antibody treatment, optionally combined with a probiotic, to enhance safety and tolerability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If a gradual dose escalation schedule is used in OIT, then adverse events are minimized, but treatment duration increases and compliance decreases
Solution Approach 1:
The patent changes the dosing parameters by using a rapid dose escalation schedule with larger dose increments and shorter intervals between doses compared to traditional gradual schedules. This allows the treatment to achieve the same immunologic tolerance faster while maintaining safety through careful monitoring and selection of appropriate dose increases based on patient response.
2Object-affected harmful factors
If anti-IgE antibody (omalizumab) is administered prior to and during OIT, then adverse events are reduced, but peanut-specific IgE levels increase upon withdrawal
Solution Approach 1:
The patent extracts and eliminates the need for anti-IgE antibody pre-treatment and concurrent administration by using a rapid dose escalation OIT schedule that achieves tolerance faster than traditional protocols. This allows the treatment to reach maintenance phase more quickly without requiring omalizumab, thereby avoiding the problem of elevated IgE levels upon withdrawal.
3Loss of time
If a rapid dose escalation phase is used, then treatment duration is decreased, but adverse event risk increases
Solution Approach 1:
The patent implements feedback mechanisms by monitoring patient response to each dose increase and adjusting the escalation schedule accordingly. Dose increases are based on individual tolerance thresholds and clinical response, allowing rapid escalation when tolerated while pausing or reducing dose when adverse events occur, thus maintaining safety while accelerating treatment.
Data Source
AI summary
The present invention concerns a method of treating peanut allergy in a subject, or a population of subjects, the method comprising administering to said subject or population of subjects a peanut allergen by an oral immunotherapy (OIT) regimen comprising a dose escalation phase in which the peanut allergen is administered in a dose which is increased in increments from an initial dose of the allergen equivalent of 5 mg peanut protein or less to a dose of the allergen equivalent of 200 mg peanut protein or more within 4 to 9 weeks from the administration of the initial dose. The treatment reduces the length of the build-up phase in peanut OIT methods and improves the likelihood or odds of the subject achieving sustained unresponsiveness.